Nicholas P. Griffin

Nicholas P. Griffin

Senior Associate
Houston, New York

Email [email protected]​hoganlovells.com

Phone 1 713 632 1488 (Houston) +1 212 918 3688 (New York)

Fax +1 713 632 1401

LanguagesBulgarian

Practice groupCorporate & Finance

Nick Griffin focuses his practice on general corporate and securities law matters, including mergers, acquisitions, public and private securities offerings, and public company reporting. The clients he represents range from early stage startups and their founders to established public reporting companies. His industry experience is focused on various aspects of the life science sector, including oncology therapies, pain products, dermatology therapies, vaccines, diagnostics, medical devices and drug/device combinations, orphan drugs, and gene therapies.

Nick has successfully negotiated and completed a range of transactions for companies in the life sciences and technology sectors, including initial public offerings (IPOs), follow-on equity offerings, at-the-market (ATM) offerings, registered debt offerings, private placements, and private investment in public equity (PIPE) deals. 

In addition to his transactional work, Nick advises public and private companies and their boards on securities law, corporate governance matters, shareholder activism issues, and general corporate strategy.

Education and admissions

Education

J.D., University of Pennsylvania Law School, 2016

B.S., Brigham Young University, 2013

Bar admissions and qualifications

New York

Texas

Representative experience

Represented Coursera Inc. in its initial public offering of 15.73 million shares of its common stock.

Represented 1stdibs.com Inc. in its initial public offering of 5.75 million shares of its common stock.

Represented Plus Therapeutics Inc. in its implementation and management of an ATM program to sell shares of common stock having a maximum aggregate gross offering price of up to US$10m.*

Represented Salarius Pharmaceuticals Inc. in its implementation and management of an ATM program to sell shares of common stock having a maximum aggregate gross offering price of up to US$6.306m.*

Represented Alcobra Ltd. in its defense against shareholder activist Brosh Capital.*

Represented Immunomedics Inc. in its defense against shareholder activist venBio Select Advisor.*

Represented Devon Energy Corp. in the US$3.125bn sale of ownership interests in EnLink Midstream Partners and EnLink Midstream to Global Infrastructure Partners.*

Issuer’s counsel in the simultaneous redemption of SunCoke Energy Partners LP’s existing senior notes and private placement of US$630m aggregate principal amount of new senior notes.*

*Matter handled prior to joining Hogan Lovells.

Loading data